Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C15H26N2 |
Molecular Weight | 234.3809 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
C1CCN2C[C@]3([H])C[C@@]([H])(CN4CCCC[C@]34[H])[C@]2([H])C1
InChI
InChIKey=SLRCCWJSBJZJBV-ZQDZILKHSA-N
InChI=1S/C15H26N2/c1-3-7-16-11-13-9-12(14(16)5-1)10-17-8-4-2-6-15(13)17/h12-15H,1-11H2/t12-,13-,14-,15+/m0/s1
Molecular Formula | C15H26N2 |
Molecular Weight | 234.3809 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 4 / 4 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionSources: http://www.drugbank.ca/drugs/DB06727Curator's Comment:: Description was created based on several sources, including
http://www.ndrugs.com/?s=spal
Sources: http://www.drugbank.ca/drugs/DB06727
Curator's Comment:: Description was created based on several sources, including
http://www.ndrugs.com/?s=spal
Sparteine is a class 1a antiarrhythmic agent; a sodium channel blocker. It is the predominant alkaloid in Lupinus mutabilis, and is thought to chelate the bivalents calcium and magnesium. It is not FDA approved for human use as an antiarrhythmic agent. It is also used as a chiral base in organic chemistry, and as a ligand in organic chemical synthesis. Marketed under the brand name Spal in Taiwan and Sparteine in Brazil.
CNS Activity
Originator
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: GO:0006814 Sources: https://www.ncbi.nlm.nih.gov/pubmed/9781689 |
168.8 µM [IC50] |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Sources: http://www.ndrugs.com/?s=spal |
Primary | Spal Approved UseIndications: arrhythmias |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
117.8 min |
200 mg single, intravenous dose: 200 mg route of administration: Intravenous experiment type: SINGLE co-administered: |
SPARTEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
|
117.45 min |
200 mg single, oral dose: 200 mg route of administration: Oral experiment type: SINGLE co-administered: |
SPARTEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: FASTED |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
50% |
single, unknown |
SPARTEINE plasma | Homo sapiens population: HEALTHY age: ADULT sex: UNKNOWN food status: UNKNOWN |
Sample Use Guides
In Vivo Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/8646830
A single 100 mg oral dose of sparteine and a single 40 mg oral dose of dextromethorphan were administered on two occasions to 12 patients
Route of Administration:
Oral
In Vitro Use Guide
Sources: https://www.ncbi.nlm.nih.gov/pubmed/7534384
Sparteine (20 uM) produced also remarkable inhibitions in the uptake of [3H]-histamine by astrocytes from rat brain.
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Jun 26 03:19:23 UTC 2021
by
admin
on
Sat Jun 26 03:19:23 UTC 2021
|
Record UNII |
298897D62S
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
C01BA04
Created by
admin on Sat Jun 26 03:19:23 UTC 2021 , Edited by admin on Sat Jun 26 03:19:23 UTC 2021
|
||
|
WHO-VATC |
QC01BA04
Created by
admin on Sat Jun 26 03:19:23 UTC 2021 , Edited by admin on Sat Jun 26 03:19:23 UTC 2021
|
||
|
NCI_THESAURUS |
C47793
Created by
admin on Sat Jun 26 03:19:23 UTC 2021 , Edited by admin on Sat Jun 26 03:19:23 UTC 2021
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
90-39-1
Created by
admin on Sat Jun 26 03:19:23 UTC 2021 , Edited by admin on Sat Jun 26 03:19:23 UTC 2021
|
PRIMARY | |||
|
DB06727
Created by
admin on Sat Jun 26 03:19:23 UTC 2021 , Edited by admin on Sat Jun 26 03:19:23 UTC 2021
|
PRIMARY | |||
|
298897D62S
Created by
admin on Sat Jun 26 03:19:23 UTC 2021 , Edited by admin on Sat Jun 26 03:19:23 UTC 2021
|
PRIMARY | |||
|
2467
Created by
admin on Sat Jun 26 03:19:23 UTC 2021 , Edited by admin on Sat Jun 26 03:19:23 UTC 2021
|
PRIMARY | |||
|
90-39-1
Created by
admin on Sat Jun 26 03:19:23 UTC 2021 , Edited by admin on Sat Jun 26 03:19:23 UTC 2021
|
PRIMARY | |||
|
CHEMBL412873
Created by
admin on Sat Jun 26 03:19:23 UTC 2021 , Edited by admin on Sat Jun 26 03:19:23 UTC 2021
|
PRIMARY | |||
|
D013034
Created by
admin on Sat Jun 26 03:19:23 UTC 2021 , Edited by admin on Sat Jun 26 03:19:23 UTC 2021
|
PRIMARY | |||
|
1447
Created by
admin on Sat Jun 26 03:19:23 UTC 2021 , Edited by admin on Sat Jun 26 03:19:23 UTC 2021
|
PRIMARY | |||
|
644020
Created by
admin on Sat Jun 26 03:19:23 UTC 2021 , Edited by admin on Sat Jun 26 03:19:23 UTC 2021
|
PRIMARY | |||
|
C152414
Created by
admin on Sat Jun 26 03:19:23 UTC 2021 , Edited by admin on Sat Jun 26 03:19:23 UTC 2021
|
PRIMARY | |||
|
SPARTEINE
Created by
admin on Sat Jun 26 03:19:23 UTC 2021 , Edited by admin on Sat Jun 26 03:19:23 UTC 2021
|
PRIMARY | |||
|
M10134
Created by
admin on Sat Jun 26 03:19:23 UTC 2021 , Edited by admin on Sat Jun 26 03:19:23 UTC 2021
|
PRIMARY | Merck Index | ||
|
201-988-8
Created by
admin on Sat Jun 26 03:19:23 UTC 2021 , Edited by admin on Sat Jun 26 03:19:23 UTC 2021
|
PRIMARY | |||
|
SUB10613MIG
Created by
admin on Sat Jun 26 03:19:23 UTC 2021 , Edited by admin on Sat Jun 26 03:19:23 UTC 2021
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
PARENT -> CONSTITUENT ALWAYS PRESENT | |||
|
SALT/SOLVATE -> PARENT |
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |